Part of Founders Combined Charity Income Common Investment Fund, Fondazione Telethon is an Italian company located in Rome that operates as a healthcare charity.\nThe company says this about itself: Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than �� 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments.

San Raffaele Hospital is one of the top centers of Gruppo San Donato (Italy’s largest hospital group, treating over 4.7 million patients yearly). San Raffaele University & Research Hospital is an institute that incorporates clinical, research and university activities altogether, while being internationally recognized for its specialization in some of the most complex pathologies. The hospital is a multi-specialty center with more than 50 clinical specialties covered and over 1300 beds, which is accredited by the Italian National Health System to provide treatment to both public and private, national and international patients. In 2016, the San Raffaele Hospital performed nearly 51,000 patient admissions, 67,700 emergency room interventions and delivered over 7 million healthcare services, including outpatient appointments and diagnostic exams. It is considered to be the most famous hospital in the country and among the most reputable medical centers in Europe.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

The Institut national de la recherche agronomique (INRA, pronounced [inʁa]; English: National Institute of Agricultural Research) is a French public research institute dedicated to agricultural science. It was founded in 1946 and is a Public Scientific and Technical Research Establishment under the joint authority of the Ministries of Research and Agriculture.

Vycellix, Inc. is an American private company located in Tampa, FL. The firm operates as a biopharmaceutical company. Evren Alici is currently the CEO of the firm.\nThe company says this about itself: Vycellix is a private, immuno-centric discovery life science company, advancing the development of transformational platform technologies to enhance and optimize next-generation cell & gene-based therapies, including T cell and natural killer (NK) cell-based cancer therapies.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. is a company headquartered in Songjiang, China. The firm provides cancer treatment services.

Fengchao Pharmaceutical Technology (Shanghai) Co., Ltd., established on 2015-08-11, The scope of business includes engaging in medical technology,Biological Technology,Ecotechnology,Chemical Technology,New Material Technology,Technology development in the field of new energy technology,technical consulting,Technical Services,technology transfer,Industrial Investment.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Medisix Therapeutics is a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Their technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Their programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Chengdu Ruisheng High-tech Co., Ltd., established on 1999-07-13, Business scope includes electronic,mechanical(Passenger cars with less than nine seats are not included),automatic control,chemical industry(Does not contain dangerous goods),Instrumentation,Development of high-tech products such as electronic computer applications,develop,Production,Sales;Research on Biotechnology Products,to develop,Production,Sales(Except for special regulations of the state);Finished Veterinary Drugs(Does not contain prophylactic biological products)promotion of.

Diadem Biotherapeutics, Inc. is an American company located in Torrance, CA, that operates biotechnology company that focuses on creating bio-therapeutically materials produced using organic means. It was founded in 2019 by Mickey Joseph Pentecost, he has been the CEO since that date.

COFCO Nutrition & Health Research Institute Co., Ltd. is a company headquartered in Beijing, China and ultimately controlled by the Government of China. The firm provides commercial physical research services.

Nanocore Biotecnologia SA develops pharmaceutical products using biotechnology and nanotechnology and analytical methodologies. It operates as a contract research organization for developing products directed for human and animal well-being and health. The firm offers services in different stages of pre-clinical phase of development of therapeutics, vaccines and diagnostic methods. Its services include formulation development based on micro and nanotechnology, method development and validation for analysis of excipients and formulations, bio analytical methods, biopharmaceutical characterization studies, stability studies and the development of bio molecules based on recombinant engineer. The company was founded in 2003 by Jos�� Maciel Rodrigues and Karla de Melo Lima and is headquartered in Campinas, Brazil.

Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Their services include gene therapy, biotechnology, rare diseases, ophthalmology, and retina.

Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.